// App-Quantinova.ai

9002 : Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

Researchers

Presenter

  • Mark A. Socinski

Principal Investigators

  • Federico Cappuzzo

  • Francisco Jorquera Orlandi

  • Daniil Stroyakovskiy

  • Naoyuki Nogami

  • Delvys Rodriguez-Abreu

  • Denis Moro-Sibilot

  • Christian A. Thomas

  • Fabrice Barlesi

  • Gene Grant Finley

  • Claudia Kelsch

  • Anthony Lee

  • Shelley Coleman

  • Yijing Shen

  • Marcin Kowanetz

  • Ariel Lopez-Chavez

  • Alan Sandler

  • Martin Reck

Medical Centers

  • Florida Hospital Cancer Institute, Orlando, FL

  • Rocky Mountain Cancer Center, Denver, CO

  • AUSL Romagna, Ravenna, Italy

  • Instituto Nacional del Torax, Santiago, Chile

  • Department of Orthopedics, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

  • Hospital Universitavio Insular De Gran Canaria, Las Palmas, Spain

  • Centre Hospitalier Universitaire de Grenoble, Grenoble, France

  • New England Cancer Specialists, Scarborough, ME

  • Hospital Nord Service Oncologie, Marseille, France

  • Allegheny Health Network Cancer Institute, Pittsburgh, PA

  • Genentech, Inc., South San Francisico, CA

  • Genentech, Inc., South San Francisico, CA

  • LungenClinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, Germany

Locations

  • Japan

  • Italy

  • Spain

  • Germany

  • United States

  • France

  • Chile

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Anaplastic lymphoma Kinase

  • Epidermal growth factor receptor

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02366143

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved